Allos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of anti-cancer therapeutics. As of December 31, 2011, the Company focused on the development and commercialization of FOLOTYN (pralatrexate injection). FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. FOLOTYN targets the inhibition of dihydrofolate reductase (DHFR), an enzyme critical in the folate pathway, thereby interfering with deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis and triggering cancer cell death. FOLOTYN can be delivered as a single agent, for which the Company has approval for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), and can be used in combination therapy regimens. On September 5, 2012, Spectrum Pharmaceuticals, Inc. acquired Allos Therapeutics, Inc.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
Phone+1-303-4266262
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Allos Therapeutics (NASDAQ:ALTH) Frequently Asked Questions
What is Allos Therapeutics' stock symbol?
Allos Therapeutics trades on the NASDAQ under the ticker symbol "ALTH."
Has Allos Therapeutics been receiving favorable news coverage?
News articles about ALTH stock have trended somewhat negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Allos Therapeutics earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.
What other stocks do shareholders of Allos Therapeutics own?
How do I buy shares of Allos Therapeutics?
Shares of ALTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Allos Therapeutics' official website?
How can I contact Allos Therapeutics?
Allos Therapeutics' mailing address is 11080 Circle Point Rd Ste 200, WESTMINSTER, CO 80020-2778, United States. The biopharmaceutical company can be reached via phone at +1-303-4266262.
MarketBeat Community Rating for Allos Therapeutics (NASDAQ ALTH)
MarketBeat's community ratings are surveys of what our community members think about Allos Therapeutics and other stocks. Vote "Outperform" if you believe ALTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
